The proteasome inhibitor BTZ has been used to treat hematologic diseases such as multiple myeloma (MM) and mantle cell lymphoma (MCL), even if some patients do not respond or develop resistance to this treatment [120]. The gene discussed is CASC3; the disease is mantle cell lymphoma.